

Please type a plus sign (+) inside this box → **[+]**

PTO/SB/05 (12/97)

Approved for use through 09/30/00. OMB 0651-0032  
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 7804

Total Pages 26

First name inventor or Application Identifier

Douglas J. Dobroszi et al.

Express Mail Label No.

EJ302199565US

## APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

1. ☒ **Fee Transmittal Form**  
(Submit an original, and a duplicate for fee processing)
2. ☒ **Specification** Total Pages 26  
(preferred arrangement set forth below)
  - Descriptive Title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☐ **Drawing(s)** (35 USC 113) Total Sheets
4. **Oath or Declaration**
  - a. ☒ **Newly UNSIGNED** (original or copy)
  - b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)  
**[Note Box 5 below]**
    - i. ☐ **DELETION OF INVENTORS**  
Signed statement attached deleting  
inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
5. ☐ **Incorporation By Reference** (useable if Box 4b is checked)

6. ☐ **Microfiche Computer Program** (Appendix)
7. **Nucleotide and/or Amino Acid Sequence Submission**  
(if applicable, all necessary)
  - a. ☐ Computer Readable copy
  - b. ☐ Paper Copy (identical to computer copy)
  - c. ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8. ☐ **Assignment Papers** (cover sheet & document(s))
9. ☐ **37 CFR 3.73(b) Statement of Power of Attorney**  
(when there is an assignee)
10. ☐ **English Translation Document** (if applicable)
11. ☐ **Information Disclosure** ☐ **Copies of IDS Statement (IDS)/PTO-1449 Citations**
12. ☐ **Preliminary Amendment**
13. ☒ **Return Receipt Postcard (MPEP 503)**  
(Should be specifically itemized)
14. ☐ **Small Entity** ☐ **Statement filed in prior application**  
Statement(s) Status still proper and desired
15. ☐ **Certified Copy of Priority Document(s)**  
(if foreign priority is claimed)
16. ☐ **Other:** .....

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.   

## 18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

or ☐ New correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME	John M. Howell				
	The Procter & Gamble Company				
	Health Care Research Center				
ADDRESS	8700 Mason-Montgomery Road				
CITY	Mason	STATE	OH	ZIP CODE	45040-9462
COUNTRY	USA	TELEPHONE	513-622-2184	FAX	513-622-3300

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

# FEE TRANSMITTAL FORM

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16 (c))	20 - 20	0	x \$22.00 =	\$0
	INDEPENDENT CLAIMS (37 CFR 1.16 (c))	3 - 3	0	x \$82.00 =	\$0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$270.00 =	\$0
				BASIC FEE (37 CFR 1.16(a))	\$790.00
	Total of above Calculations ==				\$0
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				
	TOTAL =				\$790.00

19. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-2480. A duplicate copy of this sheet is enclosed.


- a. ☒ Any patent application filing fees required under 37 CFR 1.16.  
b. ☒ Any patent application processing fees under 37 CFR 1.17.

20. The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 16-2480. A duplicate copy of this sheet is enclosed.

- a. ☒ Any patent application processing fees under 37 CFR 1.17.  
b. ☐ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).  
c. ☒ Any filing fees under 37 CFR 1.16 for presentation of extra claims.

21. The total number of duplicate copies enclosed is 5. The Commissioner is hereby authorized to make any additional copies of this sheet needed to accomplish the purposes provided for herein and to charge any fee for such copies to Deposit Account No. 16-2480.

## 22. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED


NAME	John M. Howell
SIGNATURE	
DATE	December 20, 1999

"Express Mail" mailing label number: EJ302195566US

Date of Deposit: December 20, 1999

I hereby certify that this paper/fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

John M. Howell 33.713  
Attorney/Agent mailing application Reg No

  
Signature of Attorney/Agent mailing application

## COMPOSITIONS HAVING IMPROVED STABILITY

Douglas J. Dobrozsi

Francis J. D. Bealin-Kelly

Jayant E. Khanolkar

Brian J. Robbins

Richard Sutton

TECHNICAL FIELD

The present invention pertains to improved stability of liquid compositions that deliver pharmaceutical active ingredients. These compositions have exceptional stability when used in various product forms including liquid elixirs placed into the mouth and eventually swallowed, or can be delivered via liquid-filled lozenges, metered liquid dosing devices, atomizers and liquid-releasing, edible capsules. Such compositions are particularly useful for treating symptoms associated with respiratory illnesses.

BACKGROUND OF THE INVENTION

Routes for delivering pharmaceutical actives include delivering actives by intranasal, pulmonary, buccal, sublingual, transdermal, and rectal administration. These routes tend to be used for avoiding first-pass metabolism of drugs that are swallowed. "First pass metabolism" refers to the arrangement and order of placement of the metabolizing enzymes within the body of a human, with respect to the path followed by substances that enter the gastrointestinal tract by swallowing, and are absorbed into the general blood circulation. Items swallowed by humans, including food, drink, and medicines, enter the stomach and from there flow into the intestine. Many of the chemicals associated with the food, drink, or medicine pass through the mucosal membranes in the gastrointestinal tract and into the blood in the mesenteric veins draining from the intestine. The blood flow from the mesenteric veins passes into the liver. Metabolizing enzymes in the mucosal membranes of the intestine and in the liver can chemically alter the nature of substances passing from the intestine, through the liver, and into the common blood circulation of the body. Since all swallowed medicines are subject to the metabolizing capacity of the intestinal mucosal membranes and the liver before entering the general blood circulation of the body, frequently only a small fraction of those substances go unmetabolized, and reach the general blood circulation

Avoiding first pass metabolism can increase the bioavailability, or blood concentrations of the administered compound. Metabolic formation of metabolites of the administered compound, however, can at the same time decrease. Where formation of metabolites from the first pass metabolism is desirable, avoiding the first pass metabolism is not preferred since it logically leads to lower amounts of the metabolite in the blood. Furthermore, the blood concentrations of the active substance can increase, leading to potential toxicity or side effects attributable to the active per se. Reducing the amount of active in the dose for avoiding toxicity, concomitantly decreases the circulating blood levels of the active metabolite. This results in loss of therapeutic affect and ultimately, benefit to the patient. In order to provide a medication that is effective and avoids unwanted side effects, the composition and its means of delivery must be modified.

Respiratory illnesses covers a broad range of ailments, including viral infections and allergic reaction to inhaled allergens. Viral infections in the upper respiratory tract of humans leads to illness usually referred to as colds, or influenza. Such an illness is quite common in the general population and can be the cause of significant discomfort and suffering. Allergen inhalation also negatively impacts a fair number in the population at the same or even at a greater degree than those having a viral infection.

There are no generally regarded effective and convenient methods for preventing viral infections or allergies. In the case of viral infections, the body's natural defense mechanisms fight the infection for a period of time normally ranging from 3 days to 2 weeks. This being the case, the most commonly employed medicines treat the uncomfortable, problematic symptoms of these respiratory ailments. These symptoms include stuffy and runny noses, soreness and inflammation in the nose and throat, fits of coughing, general aches in the body, fever, and headache. Of these symptoms, coughing in uncontrollable fits is considered by many to be the most problematic and uncomfortable. Coughing disrupts normal respiration, leading to increased headache and sore throat as well as loss of sleep to the sufferer and others living with the sufferer

The compositions used to treat the above mentioned symptoms generally fall into one of the following pharmacological classifications: antihistamines; decongestants; antitussives; expectorants; mucolytics; analgesics, antipyretic and anti-inflammatory agents. The compositions are manufactured in a number of product forms, the most common being liquid syrups and elixirs for swallowing, mouth drops and lozenges as well as inhalants and topical creams or lotions that release volatile agents that are inhaled through the nose into respiratory tract. The compositions are typically swallowed immediately, or slowly dissolved in the mouth. They typically contain actives such as

guaifenesin, that aids the body in the removal of excess respiratory mucus or phlegm, diphenhydramine, that lessens the negative effects including coughing and other symptoms due to histamine produced in the body in response to the viral infection, and dextromethorphan, that acts within the part of the human brain controlling the coughing reflex. Among these actives, dextromethorphan is the most commonly used active in the world for relief of cough.

Dextromethorphan, by virtue of its physicochemical, absorption, and bioavailability properties, is a very good candidate for increasing bioavailability via methods of administration other than swallowing. For example it has been reported in patents and pharmaceutical literature that substantial increases in bioavailability can be achieved using intranasal formulations; see H. Char *et al*, Nasal Delivery of 14-C dextromethorphan in Rats, Journal of Pharmaceutical Sciences 81:750, 1992.

US Patent 4,839,176, Pankhania et al. to Boots Company, issued June 13, 1989, discloses the use of bisulfites in making tablets comprising CMC that avoid degradation. US Patent 4,474,985, Keel et al., September 25, 1993 to Monsanto, discloses a process for increasing the color-free shelf life of a crude N-aminophenol. The process comprises dissolving the crude N-acetyl aminophenol in a solvent containing a reducing agent, such as meta bisulfite. US Patent 4,478,822, issued Oct. 23, 1984 and US Patent 4,474,752, issued Oct. 2, 1984 both to Haslam et al, and assigned to Merck & Co. claim gel compositions comprising polymers that provide gelling of the liquid when entering the body cavity. Disclosed is a group of microbiological preservatives including sodium bisulfite and sodium thiosulfate. The art know to the applicants does not demonstrate a specific chemical stabilization benefit by the inclusion of for solution or liquid-based product forms,

#### SUMMARY OF THE INVENTION

What has not been realized until now is that active compounds that are combined with traditional solvents can be positively impacted when particular agents are added to the compositions. Surprisingly, adding reducing agents to a liquid composition comprising pharmaceutical actives improves the active's stability in such compositions.

The compositions of the present invention provide excellent delivery of actives to oral surfaces when in for example, a peroral product form. These compositions also demonstrate excellent shelf-life when incorporated into a variety of product forms including liquid-filled lozenges, metered liquid dosing devices, atomizers and liquid-releasing, edible capsules. Such compositions are particularly useful for treating symptoms associated with respiratory illnesses.

What has not been realized until now is that after careful and diligent research into pharmaceutical, therapeutic, and side effect properties of active compounds, compositions can be made to positively improve the therapeutic effect without increased side effects or toxicity. These compounds have improved stability in the product form selected to deliver such compositions. This benefit is achieved by adding to the active containing formulation agents that promote stability of the active in the formulation. These agents are effective in reducing and even eliminating instability due to the active's oxidation degradation pathway, thereby extending the shelf life of the compositions.

One object, therefore, of the present invention is to provide improved compositions for treating the symptoms associated with respiratory ailments, particularly minimizing fits of coughing. One particularly preferred composition is in the form of an anhydrous, hydrophilic liquids in a very stable environment for rapid delivery of actives including antitussives; antihistamines (including non-sedating antihistamines); decongestants; expectorants; mucolytics; analgesic, antipyretic and anti-inflammatory agents and local anesthetics for treating the symptoms of respiratory illnesses. The compositions can be dosed using a variety of product forms and, or package delivery options. The compositions of the present invention provide desired activity while minimizing potential side effects of the active compounds. It is also an objective of the subject invention to provide methods for achieving rapid transmucosal delivery of the aforementioned compositions.

#### Definitions and Terms

The following are definitions of terms found in the present specification:

1. transmucosal delivery:

Refers to application of drugs to the mucosal membranes of the oral cavity, including buccal (cheek), lips, gums, palates, and tongue, with the goal of the drug passing through the skin covering these sites and entering the bloodstream.

2. therapeutic dose

Refers to the amount of the substance that when administered to a person in the proper form, will produce the desired effect within the body with minimal undesired side effects.

3. pharmaceutical active/active:

Refers to the chemical molecule which exerts the desired effect on the body, when administered in the proper amount and form.

4. active metabolites

Refers to the chemical species of the pharmaceutical active which is formed upon the active undergoing metabolism.

5. monomolecular dispersion

Refers to the fact that molecules of the active are free and unencumbered from diffusion by association in crystalline or amorphous solid forms, or poly molecular association.

6. percent solubility value

Refers to the equilibrium solubility limit or maximum solubility of a molecule in a solvent at usual room temperature, expressed as the weight percent of the molecule in the composition.

7. anhydrous solvent

Refers to solvents containing less than about 5 % water.

DETAILED DESCRIPTION OF THE INVENTION

Pharmaceutical Actives

The compositions of the present invention comprise pharmaceutical actives also referred to herein as "actives" for treating illnesses, particularly symptoms associated with respiratory ailments such as colds, influenza as well as allergy. These actives include those frequently used for treating the most problematic symptoms including a stuffy and runny nose, soreness and inflammation in the nose and throat, fits of coughing, general aches in the body, fever, and headache. In the present invention, when actives are combined with solvents, the actives obtain enhanced transmucosal delivery into the blood. In the case that active metabolites contribute to the desired therapeutic effect, this enhanced delivery is achieved without appreciably lowering the level of the corresponding active metabolites. Furthermore, the level of active in the blood is maintained at a level that avoids unwanted side effects brought on by too high of levels of active in the blood.

The composition comprises a pharmaceutical active and a solvent. In a particularly preferred embodiment the solvent is a hydrophilic, water-miscible, anhydrous solvent wherein the pharmaceutical active in its un-ionized form has a percent solubility value in the solvent at ambient temperature that is equal to or greater than 0.075% and the pharmaceutical active is in its free, un-ionized form as a monomolecular dispersion in the solvent.

The preferable pharmaceutical actives of the present invention have molecular weight of less than 500 grams per mole, is capable of being ionized when in an aqueous solvent and has an octanol-water partition coefficient when in the un-ionized form of at least 100. The octanol-water partition coefficient is disclosed in A. Martin, P. Bustamante, and A.H.C. Chun, Physical Pharmacy, Fourth Edition, Lea and Febiger publishers, Philadelphia, 1993, page 237; herein incorporated by reference.

The actives that comprise compositions of the present invention include actives that fall into at least one of the following pharmacological classifications: antitussives; antihistamines; non-sedating antihistamines; decongestants; expectorants; mucolytics, analgesic, antipyretic anti-inflammatory agents, local anesthetics and mixtures thereof.

- 5 References that describe the use of such actives include J. G. Hardman, *The Pharmacologic Basis of Therapeutics*, Ninth Edition, McGraw-Hill, New York, 1995. Among the actives that fall in these pharmacological classifications are those that are suited for absorption through mucosal tissues. These actives can be used alone or in combination with other actives not necessarily absorbed in this manner and may be formulated within existing  
10 formulation techniques.

- When using actives intended for mucosal absorption, the concentration of actives in the solvent portion of the composition is preferably less than or equal to 125% of the percent solubility value, more preferably less than or equal to the percent solubility value of the pharmaceutical active. To maximize the benefits of the compositions of the present  
15 invention, the active is preferably in solution as monomolecular dispersion. The absorbed actives useful in the present invention are present in the solvent system at a level from about 0.075% to about 25.0%, preferably from about 0.28% to 10.0% by weight of the composition. It is preferred that said active is in its free, un-ionized form as a monomolecular dispersion in said solvent system. In the cases where either the salt forms  
20 or ionized forms of the drug active exist, it is preferred to use the uncharged free (non salt) form of the drug in the present invention.

- Antitussives are actives of particular use for arresting uncontrollable fits coughing. Antitussives useful in the present invention include, but, are not restricted to the group consisting of codeine, dextromethorphan, dextrophan, diphenhydramine,  
25 hydrocodone, noscapine, oxycodone, pentoxifyverine and mixtures thereof. Of these antitussives, dextromethorphan is preferred. Dextromethorphan is known to have pharmacological activity as an antitussive agent and is described in US Patent 5,196,436, Smith; incorporated herein by reference. As used herein, "dextromethorphan" means racemethorphan, 3-methoxy-17-methylmorphinan (dl-cis-1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl-2H-10,4a-iminoethanophenanthrene and pharmaceutically-acceptable  
30 salts thereof. Compositions of the present comprising dextromethorphan preferably comprise from about 0.1% to about 9.3%, more preferably from about 0.26% to about 6.2% and most preferably from about 1.16% to about 4.6% dextromethorphan. Other safe and effective amounts of other cough/cold drug actives may be included in such  
35 dextromethorphan-containing compositions.



Antihistamines useful in the present invention include, but, are not restricted to the group consisting of acrivastine, azatadine, brompheniramine, chlorpheniramine, clemastine, cyproheptadine, dexbrompheniramine, dimenhydrinate, diphenhydramine, doxylamine, hydroxyzine, meclizine, pheninamine, phenyltoloxamine, promethazine, pyrilamine, tripeleminamine, triprolidine and mixtures thereof. Non-sedating antihistamines useful in the present invention include, but, are not restricted to the group consisting of astemizole, cetirizine, ebastine, fexofenadine, loratidine, terfenadine, and mixtures thereof. Decongestants useful in the present invention include, but, are not restricted to the group consisting of phenylpropanolamine, pseudoephedrine, ephedrine, phenylephrine, oxymetazoline, and mixtures thereof. Expectorants useful in the present invention include, but, are not restricted to the group consisting of ammonium chloride, guaifenesin, ipecac fluid extract, potassium iodide and mixtures thereof. Mucolytics useful in the present invention include, but, are not restricted to the group consisting of acetylcysteine, ambroxol, bromhexine and mixtures thereof. Analgesic, antipyretic and anti-inflammatory agents useful in the present invention include, but, are not restricted to the group consisting of acetaminophen, aspirin, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, ketorolac, nabumetone, naproxen, piroxicam, caffeine and mixtures thereof. Local anesthetics useful in the present invention include, but, are not restricted to the group consisting of lidocaine, benzocaine, phenol, dyclonine, benzonotatate and mixtures thereof.

#### Solvents

The un-ionized form of the pharmaceutical active is maintained using a selected group of solvents. The solvent portion of compositions of the present invention comprises from about 60% to about 99.975%, preferably from 70% to about 99% and most preferably from about 85% to about 98% by weight of the composition.

The solvent of the present invention is normally liquid at ambient or room temperatures. It is water-soluble or water-miscible. Solvents of the present invention are preferably selected from the group consisting of propylene glycol, ethanol, poly(ethylene glycol) or PEG, propylene carbonate, diethylene glycol monoethyl ether, poloxamer, glycofurol, glycerol, and mixtures thereof. Propylene glycol and ethanol is particularly preferred. There are mixtures of these solvents that are particularly preferred for certain product forms of the present invention. For example, if the product form is an elixir, liquid capsule or liquid containing lozenge, the solvent is a combination of propylene glycol, ethanol, and PEG. If the product form is a spray, the solvents is a combination of propylene glycol, ethanol, PEG and usually propylene carbonate. The level of each solvent

that makes up these mixtures is partially dependent on aesthetic benefits sought by the formulator. Most preferable are anhydrous forms of the above solvents.

#### Reducing Agents

The addition of reducing agents has been found to have a beneficial chemical stabilizing effect on the actives comprising the present invention. This phenomena surprisingly takes place where the active is in different phase than the reducing agent. For example, where the active is soluble in a non-polar environment or phase of the composition, the reducing agent selected should be a polar phase, such as water. Therefore, despite being in separate phases, the chemical stability of the active is still positively impacted. The same stability benefit is not observed when the active and the reducing agent are co-soluble in the solvent. Therefore, the reducing agents useful in the composition depend on the active selected and its solubility.

Reducing agents are substances that have a lower redox potential than the drug or adjuvant that they are intended to protect against oxidation. Thus reducing agents are more readily oxidized than the drug or adjuvant and are effective in the presence of oxidizing agents. See W. Lund, The Pharmaceutical DODEX, 12<sup>th</sup> Edition, p.290, The Pharmaceutical Press, 1994, incorporated herein by reference. Reducing agents of the present have a electrode potential value. This is defined by the Nernst equation and practically measured using standard electrochemical reference cells. The resulting values are therefore called the Standard Electrode Potential, of  $E^0$  as measured in volts of (V). Comparing standard electrode potentials for different substances can be used to assess the effectiveness of different reducing agents; see Wells, Pharmaceutical Preformulation, Ellis Horwood Limited Publishing, 1988, pp. 168-172; incorporated herein by reference. The reducing useful in the present invention have  $E^0$  value greater than about -0.119V, preferably from about -0.119V to +0.250V. Preferred reducing agents are selected from the group consisting of the salts of meta bisulfite and bisulfite, including their sodium and potassium salts, dithiothreitol, thiourea, sodium thiosulphate, thioglycolic acid, tertbutyl hydroquinone (TBHQ), acetyl cysteine, hydroquinone and mixtures thereof.

The level of reducing agents useful in the present invention is from about 0.005% to 1.000%, preferably from about 0.500% to about 0.050%, and most preferably from about 0.100% to about 0.010% by weight of the composition.

#### Optional Ingredients

Water may be used in compositions of the present invention. In the present invention the maximum level of water is about 10%, preferably from about 1% to about

10% more preferably from 5% to about 10% and most preferably from about 5% to about 8% by weight of the composition.

Ingredients normally associated with cold and influenza treatment medicines can be used with the pharmaceutical actives disclosed herein. Such ingredients are disclosed in  
 5 US Patent 5,196,436, incorporated herein by reference. Additionally, the following ingredients may be used in the present invention:

Buffers and mixtures of buffering agents, including basic buffers as single components with pKa of from 8 to 11, include triethanolamine, tromethamine, salts of amino acids, including alkaline salts of glycine, glycylglycine, glutamine or other amino  
 10 acids, alkaline salts of phosphate, carbonate and mixtures thereof. The buffers provide compositional resistance to pH changes upon dilution of the composition with saliva within the range of 8 to 10.

Sweeteners, including aspartame, saccharin and its salts, Sucralose™ (sold by the McNeil Specialty Products Co., New Brunswick, NJ); Prosweet™ (sold by the Virginia  
 15 Dare Extract Co., New York, NY); Magnasweet™ (sold by MAFCO Worldwide Corp., Licorice Division, Camden, NJ); ammonium glycyrrhizinate, its salts, Talin™ (Thaumatococcus) and its diluted products, such as Talin GA90, (sold by the Talin Food Company, Birkenhead, England); and Acesulfame K, and mixtures thereof.

Flavorants, include anise, oil of peppermint, oil of clove, eucalyptus, lemon, lime,  
 20 honey lemon, red fruit, mint, grapefruit, orange, cherry cola and mixtures thereof.

Sensory agents. Also useful herein are sensory agents selected from the group consisting of coolants, salivating agents, warming agents. Preferably these agents are present in the compositions at a level of from about 0.001% to about 10 %, preferably from about 0.1% to about 1%, by weight of the composition.

Suitable cooling agents and warming agents include carboxamides, menthols, thymol, camphor, capsicum, phenol, eucalyptus oil, benzyl alcohol, salicyl alcohol, ethanol, clove bud oil, and hexylresorcinol, ketals, diols, and mixtures thereof. Preferred  
 25 warming agents include thymol, camphor, capsicum, phenol, benzyl alcohol, salicyl alcohol, ethanol, clove bud oil, and hexylresorcinol, nicotinate esters such as benzyl  
 30 nicotinate, ketals, diols, and mixtures thereof.

Preferred coolants are the paramenthan carboxamide agents such as N-ethyl-p-menthan-3-carboxamide (WS-3 supplied by Sterling Organics), taught by U.S. Patent 4,136,163, issued January 23, 1979, to Watson et al., which is incorporated herein by reference in its entirety. Preferred coolants are the paramenthan carboxamide agents such  
 35 as N-ethyl-p-menthan-3-carboxamide. Another preferred paramenthan carboxamide agent

is N,2,3-trimethyl-2-isopropylbutanamide, known as "WS-23", and mixtures of WS-3 and WS-23.

Additional preferred coolants are selected from the group consisting of menthol, 3-1-menthoxypropane-1,2-diol, known as TK-10 supplied by Takasago Perfumery Co., Ltd., Tokyo, Japan, menthone glycerol acetal known as MGA, manufactured by Haarmann and Reimer, menthyl lactate known as Frescolat® manufactured by Haarmann and Reimer, and mixtures thereof.

Additional cooling agents include cyclic sulphones and sulfoxides and others, all of which are described in U.S. Patent 4,032,661, issued June 28, 1977, to Rowsell et al., which is herein incorporated by reference.

The terms "menthol" and "menthyl" as used herein include dextro- and levorotatory isomers of these compounds and racemic mixtures thereof.

TK-10 is described in detail in U.S. Patent 4,459,425, issued July 10, 1984 to Amano et al. and incorporated herein by reference.

Salivating agents of the present invention include Jambu® manufactured by Takasago Perfumery Co., Ltd., Tokyo, Japan.

#### METHOD OF USE

In terms of the methods of delivery of the active, it is generally accepted that oral mucosal delivery inside the mouth must be targeted to the sub-lingual region in order to achieve a very rapid therapeutic effect; see D. Harris and J.R. Robinson, Drug Delivery via the Mucus Membranes of the Oral Cavity, Journal of Pharmaceutical Sciences 81: 1, 1992. Such dosage forms are designed to be placed under the tongue, on the floor of the mouth, and held there for some extended time. The inventors have found, however, that a large increase in bioavailability with very rapid absorption can be achieved when the subject compositions are placed against any of the mucosal membranes of the mouth, even onto the tongue and swallowed. The form of the invention is a liquid elixir solution. It is intended to be applied to any of the mucosal membranes within the mouth. This can be achieved using a medicine dropper that is calibrated to indicate the proper amount to be administered, and squirting the elixir onto the tongue prior to swallowing. The elixir can be atomized into mouth and throat and then swallowed. It can be encapsulated into some sort of shell which makes it portable and convenient to transport and administer without having to measure the quantity of liquid elixir. Examples of encapsulation shell includes hard candies as are used for lozenges, gelatin, or starch-based shells. The elixir may be packaged into a small, disposable vial which can readily be opened and squirted into the mouth, the entire vial containing exactly one therapeutic dose. Typical dosage forms of the

composition of the present invention contain no more than about 3 ml., preferable from about 0.2 ml. to about 3ml.

- One preferred form is to encapsulate the liquid into a shell of hard candy or gelatin. The shell containing substances to pretreat the mucosa and thereby enhance the absorption of the active from the liquid center. The pretreatment occurs by sucking or chewing the shell material, and the advantage is gained by separating in time the treatment of the mucosa, which occurs first, followed by the presentation of the active to be absorbed. Examples of substances for pretreatment of the mucosal membranes are membrane penetration enhancers that are commonly known in the art, examples including menthol, peppermint oil, surfactants such as polysorbate 80 or poloxamer. Another example of a mucosal membrane pretreatment are buffers as listed above, which would precondition salivary micro environment pH in the range of 8 to 11.

### EXAMPLES

#### Example I

##### Liquid Elixir

Item #	Material	% Comp. (w/w)
1	Propylene Glycol	80.764
2	Ethanol (100 %)	9.000
3	Purified Water	5.000
4	Sodium Metabisulfite	0.050
5	Sodium Saccharin	0.650
6	Peppermint Flavorant	2.000
7	Acesulfame K <sup>1</sup>	0.450
8	Takasago 10 <sup>2</sup>	0.100
9	Methone Glycerine Acetal	0.300
10	Ethyl Methane Carboxamide	0.070
11	Monoammonium Glycyrrhizinate	0.150
12	Dextromethorphan Base	1.466

Total 100.000

- 15 1 Acesulfame K available Nutrinova Inc Company of Somerset, NJ-08873, USA  
2 TK 10 available from Takasago Company of Rockleigh, NJ-07657, USA

Add a portion of Ethanol to the active (Dextromethorphan base) and solid sweetening agents (Sucralose, Monoammonium glycyrrhizinate) and continuously mix at low heat (30°C). To this vessel add the Propylene Glycol and liquid sweeteners (Pro-sweet

Liquid K). Add the reducing agent (meta bisulfite) and water together and mix until uniform. Add the mixture to the vessel and mix for about 2 hours time. Add a premix of flavorants and colorants in the remaining portion of ethanol, and add to the vessel containing the nearly completed solution. Mix until a homogenous solution is obtained.

- 5 Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Filter the composition through a US # 100 mesh sieve (product density = 1.07 g/ml.). Fill into amber glass bottles, and cap with an integrated cap / calibrated medicine dropper assembly.

About 1.5 grams of the elixir dropped onto the tongue and then swallowed.

- 10 Dextromethorphan is rapidly absorbed into the blood.

### Example II

#### Liquid Elixir

Item #	Material	% Comp. (w/w)
1	Dextromethorphan Base	2.055
2	Ethanol (100 %)	10.000
3	Propylene Glycol	83.275
4	Sodium Meta Bisulfite	0.010
5	Triethanolamine	3.740
6	Sucralose	0.150
7	Pro-Sweet Liquid K	0.700
8	Monoammonium Glycyrhizinate	0.050
9	Flavorant	0.015
10	Colorant	0.005

Total 100.000

- 15 Add a portion of Ethanol to the active (Dextromethorphan base) and solid sweetening agents (Sucralose, Monoammonium glycyrrhizinate) and continuously mixed at low heat (30°C). To this vessel add the Propylene Glycol, liquid sweeteners (Pro-sweet Liquid K), and buffer (Triethanolamine, a liquid). Add the metabisulfide and mix until all materials are in solution, about 2 hours time. Add a premix of flavorants and colorants in the remaining portion of ethanol, and add to the vessel containing the nearly completed solution. Mix until a homogenous solution is obtained. Allow the composition to reside in the mixing vessel, open to the atmosphere for about

10 minutes. Mix until a homogenous solution is obtained, and filter through a US # 100 mesh sieve (product density = 1.07 g/ml.). Fill into amber glass bottles, and cap with an integrated cap / calibrated medicine dropper assembly.

About 1.0 ml. of the elixir dropped onto the tongue and then swallowed.

- 5 Dextromethorphan is rapidly absorbed into the blood.

### Example III

#### Liquid Spray

Item #	Material	% Comp. (w/w)
1	Dextromethorphan Base	3.425
2	Thioglycerol	0.050
3	Propylene Glycol	95.335
5	Sucralose	0.300
6	Pro-Sweet Liquid K	0.700
7	Monoammonium Glycyrhizinate	0.050
8	Flavorant	0.015
9	Colorant <sup>1</sup>	0.005
Total		100.000

1. Green Shade CSL-15689 obtained from the Warner Jenkins Co., St. Louis, MO, USA.

- Add a portion of propylene glycol to the active (Dextromethorphan base) and solid sweetening agents (Sucralose, Monoammonium glycyrrhizinate) and continuously mixed at low heat (30°C). To this vessel add the additional propylene glycol and liquid sweeteners (Pro-sweet Liquid K). Add the thioglycerol and mix until all materials are in solution, about 2 hours time. Add a premix of flavorants and colorants in the remaining portion of ethanol, and add to the vessel containing the nearly completed solution. Mix until a homogenous solution is obtained. Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Mix until a homogenous solution is obtained, and filter through a US # 100 mesh sieve (product density = 1.075 g/ml.). Fill into manually operated atomization pump and bottle. An example is manufactured by Calmar-Albert GmbH, the Mistette Mark II fitted with a 16 mm high viscosity head assembly which delivers 0.2 ml./actuation.

Three individual actuations are sprayed into the mouth. Dextromethorphan is rapidly absorbed into the blood, and during spraying some portion of the sprayed liquid

contacts the throat area, providing the additional benefit such as numbing of the irritated cough receptors there.

#### Example IV

##### Liquid Spray

Item #	Material	% Comp. (w/w)
1	Dextromethorphan Base	3.425
2	Ethanol (100 %)	5.350
3	Propylene Glycol	41.315
4	Propylene Carbonate	40.000
5	Triethanolamine	3.740
6	Thioglycerol	0.050
7	Sucralose	0.300
8	Pro-Sweet Liquid K	0.700
9	Monoammonium Glycyrrhizinate	0.050
10	Flavorant	0.015
11	Purified Water	5.000
12	Potassium Metabisulfite	0.050
13	Colorant	0.005

Total 100.000

- 5 Add a portion of Ethanol to the active (Dextromethorphan base) and solid sweetening agents (Sucralose, Monoammonium glycyrrizinate) and continuously mixed at low heat (30°C). To this vessel add the additional Propylene Carbonate and Propylene Glycol, liquid sweeteners (Pro-sweet Liquid K) reducing agent and buffer (Triethanolamine, a liquid). Mix until all materials are in solution, about 2 hours time.
- 10 Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Prepare a premix of flavorants and colorants in the remaining portion of ethanol, and add to the vessel containing the nearly completed solution. Mix until a homogenous solution is obtained, and filter through a US # 100 mesh sieve (product density = 1.075 g/ml.). Fill into manually operated atomization pump and bottle. An example is
- 15 manufactured by Calmar-Albert GmbH, the Mistette Mark II fitted with a 16 mm high viscosity head assembly.

Three individual actuations are sprayed into the mouth. Dextromethorphan is rapidly absorbed into the blood, and during spraying some portion of the sprayed liquid



contacts the throat area, providing the additional benefit such as numbing of the irritated cough receptors there.

### Example V

#### Liquid Centered Lozenge

Item #	Material	% Comp. (w/w)
1	Dextromethorphan Base	2.055
2	Ethanol (100 %)	2.000
3	Purified Water	5.000
4	Propylene Glycol	84.825
5	Sodium Metabisulfite	0.050
6	Sucralose	0.300
7	Pro-Sweet Liquid K	0.700
8	Monoammonium Glycyrhizinate	0.050
9	Flavorant	0.015
10	Colorant	0.005

Total 100.000

- Add a portion of Ethanol to the active (Dextromethorphan base) and solid sweetening agents (Sucralose, Monoammonium glycyrrhizinate) and continuously mixed at low heat (30°C). To this vessel add the Propylene Glycol, and liquid sweeteners (Pro-sweet Liquid K). Mix until all materials are in solution, about 2 hours time. Mix until a homogenous solution is obtained. Prepare a premix of flavorants and colorants in the remaining portion of ethanol, sodium metabisulfite and water, and add to the vessel containing the nearly completed solution. Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Mix until a homogenous solution is obtained, and filter through a US # 100 mesh sieve (product density = 1.07 g/ml.). Make individual filled lozenges containing about 1.0 ml. of liquid per lozenge by a commonly used method such as extrusion

- A person places a liquid filled lozenge into the mouth and sucks on the lozenge until the liquid fill is released. Some cough relief is obtained through the action of sucking on the shell of the lozenge. When the liquid center is released, dextromethorphan is rapidly absorbed into the blood.

**Example VI****Liquid Centered Lozenge**

Item #	Material	% Comp. (w/w)
1	Dextromethorphan Base	2.055
2	Ethanol (100 %)	2.000
3	Purified Water	5.000
4	Propylene Glycol	84.875
5	Sodium Metabisulfite	0.050
6	Sucralose	0.300
7	Pro-Sweet Liquid K	0.700
8	Monoammonium Glycyrrhizinate	0.050
9	Flavorant	0.015
10	Colorant	0.005

Total 100.000

- Add a portion of Ethanol to the active (Dextromethorphan Base) and solid sweetening agents (Sucralose, Monoammonium glycyrrhizinate) and continuously mixed at low heat (30°C). To this vessel add the Propylene Glycol, and liquid sweeteners (Pro-sweet Liquid K). Prepare an aqueous premix of sodium metabisulfite and add to the vessel. Mix until all materials are in solution, about 2 hours time. Prepare a premix of flavorants and colorants in the remaining portion of ethanol, and add to the vessel containing the nearly completed solution. Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Mix until a homogenous solution is obtained, and filter through a US # 100 mesh sieve (product density = 1.07 g/ml.). Make individual filled lozenges containing about 1.0 ml. of liquid per lozenge by a commonly used method such as extrusion

- A person places a liquid filled lozenge into the mouth and sucks until the liquid fill is released. Some cough relief is obtained through the action of sucking on the shell of the lozenge. When the liquid center is released, dextromethorphan is rapidly absorbed into the blood, and relief from coughing is obtained within 10 minutes time.

**Example VII****Liquid Elixir**

Items #	Material	% Comp. (w/w)

1	Dextromethorphan Base	2.055
2	Pseudoephedrine Base	4.593
3	Ethanol (100%)	10.000
4	Propylene Glycol	5.000
5	Triethanolamine	3.740
6	Sucralose	0.150
7	Pro-Sweet Liquid K	0.700
8	Monoammonium Glycyrhizinate	0.050
9	Flavorant	0.015
10	Colorant	0.005
11	Sodium Metabisulfite	0.050
Total		100.000

- Add a portion of Ethanol to the active (Dextromethorphan base & Pseudoephedrine base) and solid sweetening agents (Sucralose, Monoammonium glycyrrhizinate) and continuously mixed at low heat (30°C). To this vessel add the bulk of the propylene glycol, liquid sweeteners (Pro-sweet Liquid K), and buffer (Triethanolamine, a liquid). Mix until all materials are in solution, about 2 hours time. Prepare a premix of flavorants and colorants in the remaining portions of propylene glycol and ethanol, as well as the sodium metabisulfite and add to the vessel containing the nearly completed solution. Mix until a homogenous solution is obtained, and filter through a US # 100 mesh sieve (product density = 1.07 g/ml). Fill into amber glass bottles, and cap with an integrated cap / calibrated medicine dropper assembly.

About 1.0 ml. of the elixir dropped onto the tongue and then swallowed.

#### Example VIII

##### Liquid Elixir

Items #	Material	% Comp.
		(w/w)
1	Chlorpheniramine Base	0.263
2	Pseudoephedrine Base	4.593
3	Ethanol (100%)	10.000
4	Propylene Glycol	5.000
5	Sucralose	0.150
6	Pro-Sweet Liquid K	0.700
7	Monoammonium Glycyrhizinate	0.050

8	Flavorant	0.015
9	Colorant	0.005
10	Sodium Bisulfite	0.050
Total		100.000

Add a portion of Ethanol to the actives (Chlorpheniramine base & Pseudoephedrine base) and solid sweetening agents (Sucralose, Monoammonium glycyrrhizinate) and continuously mixed at low heat (30°C). To this vessel add the bulk of the propylene glycol, liquid sweeteners (Pro-sweet Liquid K), sodium bisulfite and buffer (Triethanolamine, a liquid). Mix until all materials are in solution, about 2 hours time. Prepare a premix of flavorants and colorants in the propylene glycol and remaining portion of ethanol, and add to the vessel containing the nearly completed solution. Mix until a homogenous solution is obtained, and filter through a US # 100 mesh sieve (product density = 1.07 g/ml.). Fill into amber glass bottles, and cap with an integrated cap / calibrated medicine dropper assembly.

About 1.0 ml. of the elixir dropped onto the tongue and then swallowed.  
Chlorpheniramine & pseudoephedrine is rapidly absorbed into the blood.

#### Example IX

##### Liquid Elixir

Items #	Material	% Comp.
		(w/w)
1	Acetaminophen	27.169
2	Dextromethorphan Base	1.195
2	Pseudoephedrine Base	2.671
3	Ethanol (100%)	10.000
4	Propylene Glycol	52.034
5	Polyvinyl pyrrolidone <sup>2</sup>	2.170
6	Triethanolamine	3.740
7	Sucralose	0.150
8	Pro-Sweet Liquid K	0.700
9	Monoammonium Glycyrrhizinate	0.050
10	Flavorant	0.015
11	Colorant	0.005
12	Sodium Metabisulfite	0.100
Total		100.000

1. Carbowax Sentry Polyethylene available from Unio Carbide, Mooretown NJ, USA.

2. PVP-K17PF available from BASF Corp.

- Dissolve Dextromethorphan Base and Pseudoephedrine Base in portion of alcohol to make a premix. In separate container heat propylene glycol to about 70°C. Once all material is melted and in clear liquid form add Acetoammonophen and continue to heat to 110-120 °C with continuous mixing. Remove heat once liquid is clear. Cool it to room temperature. Add the mixture to the Dextromethorphan and Pseudoephedrine. Also add liquid sweetener (Pro-sweet Liquid K) and buffer (Triethanolamine).

- Mix until all materials are in solution. Prepare a premix of flavorants and colorants in the remaining portion of alcohol and sodium metabisulfite, and add to the vessel containing the nearly completed solution. Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Mix until homogeneous and filter through a US #100 mesh sieve. Fill in a amber glass bottles, and cap with an integrated cap/ calibrated medicine dropper assembly. About 1.84 grams of the elixir is dropped onto the tongue and then swallowed.

**Example X**

Liquid Elixir

Items #	Material	% Comp.
		(w/w)
1	Ethanol (100%)	88.484
2	Water	10.00
3	Dextromethorphan Base	1.466
4	Meta Bisulphite	0.05
Total		100.000

- Dissolve Dextromethorphan Base in portion of alcohol to make a premix. In separate container heat water and meta Bisulfite to about 70°C. Mix until uniform and cool to room temperature. Add this mixture to the Dextromethorphan Base.

- Mix until all materials are in solution. Add the remaining portion of alcohol and sodium metabisulfite to the vessel containing the nearly completed solution. Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Mix until homogeneous and filter through a US #100 mesh sieve. Fill in a amber glass bottles, and cap with an integrated cap/ calibrated medicine dropper assembly. About 1.84 grams of the elixir is dropped onto the tongue and then swallowed.

**Example XI**

## Liquid Elixir

Items #	Material	% Comp.
		(w/w)
1	Ethanol (100%)	88.484
2	Water	10.00
3	Dex base	1.466
4	Metabisulphite	0.05
5	Aesthetics package <sup>1</sup>	4.000
Total		100.000

1. see above examples

Dissolve Dextromethorphan Base in portion of alcohol to make a premix. In separate container heat water and meta Bisulfite to about 70°C. Mix until uniform and cool to room temperature. Add this mixture to the Dextromethorphan Base.

Mix until all materials are in solution. Add the remaining portion of alcohol, sodium metabisulfite and the aesthetics package to the vessel containing the nearly completed solution. Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Mix until homogeneous and filter through a US #100 mesh sieve. Fill in a amber glass bottles, and cap with an integrated cap/ calibrated medicine dropper assembly. About 1.84 grams of the elixir is dropped onto the tongue and then swallowed.

**Example XII**

chewable soft gellatin capsules

Items #	Material	% Comp.
		(w/w)
1	Propylene Glycol	35.109
2	Glycerine	10.000
3	Dextromethorphan Base	1.100
4	Acetoaminophen Base	32.500
5	Pseudoephedrine Base	2.458
6	Polyvinyl pyrrolidone	4.170
7	Aesthetics package <sup>1</sup>	4.000

8	Water	10.000
9	Potassium Metabisulfite	0.050
Total		100.000

1. see above examples

- Dissolve Dextromethorphan Base in portion of alcohol to make a premix. In separate container heat water and meta Bisulfite to about 70°C. Add acetoamophen and continue to heat to 110-120 °C with continuous mixing. Remove heat once liquid is clear. Cool it to room temperature. Add the mixture to the Dextromethorphan and Pseudoephedrine Mix until uniform and cool to room temperature. Mix until all materials are in solution. Add the remaining portion of alcohol, polyvinyl pyrrolidone, sodium metabisulfite and the aesthetics package to the vessel containing the nearly completed solution. Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Mix until homogeneous and filter through a US #100 mesh sieve. Fill chewable soft gellatin capsules using the above formulation. Said gelatin capsules are available from the trade by companies such as R. P. Scherer, of St. Petersburg, Florida. About 1.84 grams of the elixir is delivered to the mouth by mastication of the capsule(s) and then swallowed.

### Example XIII

chewable soft gellatin capsules

Items #	Material	% Comp.
		(w/w)
1	Propylene Glycol	74.950
2	Glycerine	10.000
3	Dextromethorphan Base	1.100
4	Aesthetics package <sup>1</sup>	4.000
5	Water	10.000
9	Potassium Metabisulfite	0.050
Total		100.000

1. see above examples

- Dissolve Dextromethorphan Base in portion of alcohol to make a premix. In separate container heat water and Meta Bisulfite to about 70°C. Remove heat once liquid is clear. Cool it to room temperature. Add the mixture to the Dextromethorphan. Mix until uniform and cool to room temperature. Mix until all materials are in solution. Add the

- remaining portion of alcohol and the aesthetics package to the vessel containing the nearly completed solution. Allow the composition to reside in the mixing vessel, open to the atmosphere for about 10 minutes. Mix until homogeneous and filter through a US #100 mesh sieve. Fill chewable soft gellatin capsules using the above formulation. Said gelatin capsules are available from the trade by companies such as R. P. Scherer, of St. Petersburg, Florida. About 1.84 grams of the elixir is delivered to the mouth by mastication of the capsule(s) and then swallowed.

WE CLAIM:

1. A method of preparing a composition for use in the treatment of a disease, comprising the steps of:  
 (a) combining a first component and a second component in a mixing vessel;  
 (b) allowing the composition to reside in the mixing vessel, open to the atmosphere, for about 10 minutes;  
 (c) mixing the composition until homogeneous;  
 (d) filtering the composition through a US #100 mesh sieve;  
 (e) filling chewable soft gellatin capsules using the above formulation;  
 (f) delivering the capsules to the mouth by mastication of the capsule(s); and  
 (g) swallowing the capsules.



1. A liquid composition having improved stability comprising a pharmaceutical active, solvent to solubilize said active, and a reducing agent to improve said active stability in said composition.
2. An oral composition having improved stability comprising a pharmaceutical active, solvent to solubilize said active, and a reducing agent to improve said active stability in said composition.
3. The composition according to claim 1 wherein the reducing agent has an  $E^0$  value of greater than -0.119V.
4. The composition according to claim 3 wherein the reducing agent has an  $E^0$  value from about -0.119V to +0.250V.
5. The composition according to claim 4 wherein the reducing agent is selected from the group consisting of the salts of meta bisulfite and bisulfite, including their sodium and potassium salts; dithiothreitol; thiourea; sodium thiosulphate; thioglycolic acid; terbutyl hydroquinone (TBHQ); acetyl cysteine; hydroquinone and mixtures thereof.
6. The composition according to claim 5 wherein the reducing agent comprises from about 0.005% to 1.000% of the composition.
7. The composition according to claim 6 wherein the reducing agent comprises from about 0.100% to about 0.01% by weight of the composition.
8. A composition according to claim 5 comprising a pharmaceutical active in a hydrophilic, water-miscible, anhydrous solvent wherein the pharmaceutical active in its un-ionized form has a percent solubility value in the solvent at ambient temperature that is equal to or greater than 0.075% and the pharmaceutical active is in it free, un-ionized form as a monomolecular dispersion in the solvent and said water.

9. The composition according to claim 8 wherein the pharmaceutical actives have a molecular weight of less than 500 grams per mole, is capable of being ionized when in an aqueous solvent and has an octanol-water partition coefficient when in the un-ionized form of at least 100.
10. The composition according to claim 9 wherein the pharmaceutical actives are selected from the group consisting of antitussives, antihistamines, non-sedating antihistamines, decongestants, expectorants, analgesic mucolytics, antipyretic anti-inflammatory agents, local anesthetics and mixtures thereof.
11. The composition according to claim 10 wherein the concentration of pharmaceutical actives in the solvent is less than or equal to 125% of the percent solubility value of said active.
12. The composition according to claim 11 wherein the pharmaceutical active is present in the solvent at a level from about 0.075% to about 25.0% by weight of the composition.
13. The composition according to claim 12 wherein the pharmaceutical active is present in the solvent at a level from about 0.28% to 10.0%.
14. The composition according to claim 13 wherein the solvent comprises from about 60% to about 99.975% by weight of the composition.
15. The composition according to claim 14 wherein the comprises from about 70% to about 99% by weight of the composition.
16. The composition according to claim 15 wherein the solvent comprises from about 85% to about 98% by weight of the composition.
18. The composition according to claim 15 wherein the solvent is hydrophilic, water-miscible, and anhydrous selected from the group consisting propylene glycol, ethanol, poly(ethylene glycol) or PEG, propylene carbonate, diethylene glycol monoethyl ether, poloxamer, glycofurol, glycerol and mixtures thereof.

19. A method for treating respiratory illnesses using the composition of claim 2 wherein the method comprises oral administration of said composition having a total dosage volume of no more than 3.0 mLs.
20. The method according to claim 19 wherein the composition is placed against any of the mucosal membranes of the mouth.

## ABSTRACT

### COMPOSITIONS HAVING IMPROVED DELIVERY OF ACTIVES

The present invention pertains to liquid compositions having improved delivery of pharmaceutical actives. These compositions comprise pharmaceutical actives, solvent and a reducing agent. These compositions may take the form of liquid elixirs placed into the mouth by liquid-filled drops, metered liquid dosing devices, atomizers and liquid-releasing, edible capsules.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2

## DECLARATION COMBINED WITH POWER OF ATTORNEY

Page 1 of 2

Attorney Docket No. 7804

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Composition Having Improved Stability the specification of which

(check ☒ [X] is attached hereto.one) ☐ [ ]

was filed on \_\_\_\_\_ as U.S. Application

Serial No. or PCT Int'l Application No. \_\_\_\_\_

and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37 Code of Federal Regulations §1.56.

I hereby claim foreign priority benefits under Title 35 United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one other country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)Priority Claimed

(Number) \_\_\_\_\_

(Country) \_\_\_\_\_

(Day/Month/Year Filed) \_\_\_\_\_

☐ [ ]

Yes

☐ [ ]

No

(Number) \_\_\_\_\_

(Country) \_\_\_\_\_

(Day/Month/Year Filed) \_\_\_\_\_

☐ [ ]

Yes

☐ [ ]

No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Serial No.Filing DateApplication Serial No.Filing Date

60/156,540

9/29/99

60/115,378

1/11/99

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.) \_\_\_\_\_

(Filing Date) \_\_\_\_\_

(Status) (patented, pending, abandoned) \_\_\_\_\_

As named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

<u>Att'y Name</u>	<u>Att'y Reg Number</u>	<u>Associate Power of Attorney Attached</u>
John M. Howell	33,713	<input type="checkbox"/> [ ] Yes <input checked="" type="checkbox"/> [X] No
Brahm J. Corstanje	34,804	
Jacobus C. Rasser	37,043	
T. David Reed	32,931	
Timothy B. Guffey	41,048	

SEND CORRESPONDENCE TO:

The Procter & Gamble Company(513) 622-2184Mr. John M. HowellPhone No.8700 Mason-Montgomery Rd. Mason OH 45040-9462StreetCityStateZip Code

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor Douglas Joseph Dobrozsi  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence 9273 Kempergrove Lane, Loveland, OH 45140  
Citizenship USA  
Post Office Address The Procter & Gamble Company, Health Care Research Center  
P. O. Box 8006, Mason, OH 45040-8006

Full name of second joint inventor, if any Francis Joseph David Bealin-Kelly  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence 128 Cottimore Ave., Walton on Thames, Surrey KT12 2AG, ENGLAND  
Citizenship Republic of Ireland and UK  
Post Office Address The Procter & Gamble Company, Health Care Research Center  
P. O. Box 8006, Mason, OH 45040-8006

Full name of third joint inventor, if any Jayant Eknath Khanolkar  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence Flat No. 12A, Avenue Elmers, Surbiton, KT6 4SP, England  
Citizenship India  
Post Office Address The Procter & Gamble Company, Health Care Research Center  
P. O. Box 8006, Mason, OH 45040-8006

Full name of fourth joint inventor, if any Brian James Robbins  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence 17 Kestrel Avenue, Staines, Middlesex, TW18 4RU, England  
Citizenship UK  
Post Office Address The Procter & Gamble Company, Health Care Research Center  
P. O. Box 8006, Mason, OH 45040-8006

Full name of fifth joint inventor, if any Richard Sutton  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence \_\_\_\_\_  
Citizenship \_\_\_\_\_  
Post Office Address The Procter & Gamble Company, Health Care Research Center  
P. O. Box 8006, Mason, OH 45040-8006